Circumventing Cancer Drug Resistance in the Era of Personalized Medicine

被引:375
作者
Garraway, Levi A. [1 ,2 ,5 ,6 ]
Jaenne, Pasi A. [1 ,3 ,4 ,5 ]
机构
[1] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA
[2] Dana Farber Canc Inst, Ctr Canc Genome Discovery, Boston, MA 02215 USA
[3] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA 02215 USA
[4] Dana Farber Canc Inst, Belfer Inst Appl Canc Sci, Boston, MA 02215 USA
[5] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA
[6] Broad Inst Harvard & MIT, Cambridge, MA USA
关键词
GROWTH-FACTOR-RECEPTOR; CHRONIC MYELOID-LEUKEMIA; TYROSINE KINASE INHIBITORS; CELL LUNG-CANCER; ACQUIRED-RESISTANCE; BCR-ABL; MULTIDRUG-RESISTANCE; MET AMPLIFICATION; BREAST-CANCER; GEFITINIB RESISTANCE;
D O I
10.1158/2159-8290.CD-12-0012
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
All successful cancer therapies are limited by the development of drug resistance. The increase in the understanding of the molecular and biochemical bases of drug efficacy has also facilitated studies elucidating the mechanism(s) of drug resistance. Experimental approaches that can help predict the eventual clinical drug resistance, coupled with the evolution of systematic genomic and proteomic technologies, are rapidly identifying novel resistance mechanisms. In this review, we provide a historical background on drug resistance and a framework for understanding the common ways by which cancers develop resistance to targeted therapies. We further discuss advantages and disadvantages of experimental strategies that can be used to identify drug resistance mechanism(s). Significance: Increased knowledge of drug resistance mechanisms will aid in the development of effective therapies for patients with cancer. We provide a summary of current knowledge on drug resistance mechanisms and experimental strategies to identify and study additional drug resistance pathways. Cancer Discovery; 2(3); 214-26. (c) 2012 AACR.
引用
收藏
页码:214 / 226
页数:13
相关论文
共 93 条
[1]  
[Anonymous], J CLIN ONCOL
[2]   Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL [J].
Azam, M ;
Latek, RR ;
Daley, GQ .
CELL, 2003, 112 (06) :831-843
[3]   MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib [J].
Bean, James ;
Brennan, Cameron ;
Shih, Jin-Yuan ;
Riely, Gregory ;
Viale, Agnes ;
Wang, Lu ;
Chitale, Dhananjay ;
Motoi, Noriko ;
Szoke, Janos ;
Broderick, Stephen ;
Balak, Marissa ;
Chang, Wen-Cheng ;
Yu, Chong-Jen ;
Gazdar, Adi ;
Pass, Harvey ;
Rusch, Valerie ;
Gerald, William ;
Huang, Shiu-Feng ;
Yang, Pan-Chyr ;
Miller, Vincent ;
Ladany, Marc ;
Yang, Chih-Hsin ;
Pao, William .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (52) :20932-20937
[4]   Verapamil increases the survival of patients with anthracycline-resistant metastatic breast carcinoma [J].
Belpomme, D ;
Gauthier, S ;
Pujade-Lauraine, E ;
Facchini, T ;
Goudier, MJ ;
Krakowski, I ;
Netter-Pinon, G ;
Frenay, M ;
Gousset, C ;
Marié, FN ;
Benmiloud, M ;
Sturtz, F .
ANNALS OF ONCOLOGY, 2000, 11 (11) :1471-1476
[5]   A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer [J].
Berns, Katrien ;
Horlings, Hugo M. ;
Hennessy, Bryan T. ;
Madiredjo, Mandy ;
Hijmans, E. Marielle ;
Beelen, Karin ;
Linn, Sabine C. ;
Gonzalez-Angulo, Ana Maria ;
Stemke-Hale, Katherine ;
Hauptmann, Michael ;
Beijersbergen, Roderick L. ;
Mills, Gordon B. ;
de Vijver, Marc J. van ;
Bernards, Rene .
CANCER CELL, 2007, 12 (04) :395-402
[6]   FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR [J].
Bivona, Trever G. ;
Hieronymus, Haley ;
Parker, Joel ;
Chang, Kenneth ;
Taron, Miquel ;
Rosell, Rafael ;
Moonsamy, Philicia ;
Dahlman, Kimberly ;
Miller, Vincent A. ;
Costa, Carlota ;
Hannon, Gregory ;
Sawyers, Charles L. .
NATURE, 2011, 471 (7339) :523-526
[7]  
BLADE J, 1983, CANCER-AM CANCER SOC, V52, P786, DOI 10.1002/1097-0142(19830901)52:5<786::AID-CNCR2820520505>3.0.CO
[8]  
2-H
[9]   Comparison of imatinib, mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen:: high efficacy of drug combinations [J].
Bradeen, Heather A. ;
Eide, Christopher A. ;
O'Hare, Thomas ;
Johnson, Kara J. ;
Willis, Stephanie G. ;
Lee, Francis Y. ;
Druker, Brian J. ;
Deininger, Michael W. .
BLOOD, 2006, 108 (07) :2332-2338
[10]   Differential Inhibitor Sensitivity of Anaplastic Lymphoma Kinase Variants Found in Neuroblastoma [J].
Bresler, Scott C. ;
Wood, Andrew C. ;
Haglund, Elizabeth A. ;
Courtright, Joshua ;
Belcastro, Lili T. ;
Plegaria, Jefferson S. ;
Cole, Kristina ;
Toporovskaya, Yana ;
Zhao, Huaqing ;
Carpenter, Erica L. ;
Christensen, James G. ;
Maris, John M. ;
Lemmon, Mark A. ;
Mosse, Yael P. .
SCIENCE TRANSLATIONAL MEDICINE, 2011, 3 (108)